Is KRAS up or down today?
KRAS is down 0.37% today, last at 152.79. This stock moved -0.37% versus the prior close.
KRAS · KRAS
KRAS (KRAS) is trading at 152.79, down 0.37% on the session. KRAS sits at the 50% mark of its 52-week range.
Leading the coverage: “KRAS Cancer Trial Partnership Might Change The Case For Investing In Incyte (INCY) - Simply Wall St” (Google News Earnings, 8d ago). KRAS is +4.04% since story.
KRAS trades on a trailing P/E of 13.5.
Analyst firms are mostly reiterating — no strong directional shift lately.
KRAS is down 0.37% today, last at 152.79. This stock moved -0.37% versus the prior close.
Leading the coverage: “KRAS Cancer Trial Partnership Might Change The Case For Investing In Incyte (INCY) - Simply Wall St” (Google News Earnings, 8d ago). KRAS is +4.04% since story. Dominant story: PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium - Yahoo Finance (1 source, neutral) RSI unavailable Price sits at 50% of its 52-week range Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Historical price chart unavailable
Live quote in the header is real, but OHLC history could not be loaded from Yahoo Finance or fallback providers. Charts use Yahoo when configured correctly — check server logs for provider errors.
PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium - Yahoo Finance
Edible Garden CEO Jim Kras to Discuss Innovation and Diversification at 2026 CEAg World Conference & Expo - Yahoo Finance
KRAS faces regulatory scrutiny over new product
KRAS volatility spikes as options activity jumps
Institutional buyers pile into KRAS, filings show